1 / 5

Clinical presentation & outcomes of stent thrombosis Spanish registry ESTROFA (n=23,500)

Clinical presentation & outcomes of stent thrombosis Spanish registry ESTROFA (n=23,500). Overall (n=301). Acute/Subacute (n=149). Late (n=152). p. Presentation. STEMI. 83.7%. 86%. 81.5%. 0.36. Shock. 20.5%. 21%. 20.4%. 0.98. TIMI 0/1. 88%. 92%. 84.2%. 0.056. Outcomes.

brendan-austin
Download Presentation

Clinical presentation & outcomes of stent thrombosis Spanish registry ESTROFA (n=23,500)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical presentation & outcomes of stent thrombosisSpanish registry ESTROFA (n=23,500) Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation STEMI 83.7% 86% 81.5% 0.36 Shock 20.5% 21% 20.4% 0.98 TIMI 0/1 88% 92% 84.2% 0.056 Outcomes In-hospital Death 11.6% 13% 9.8% Thrombosis 1.66% 2.7% 0.66% Follow-up n=216 n=128 n=133 Time, mo 11.810 1511 8.87.6 Death 16% 18.8% 13.1% Thrombosis 4.6% 6% 3.3% J Am Coll Cardiol 2008;51:986–90

  2. DECREASE Study Design The patients undergoing successful DES implantation Operator decisions for adding cilostazol Triple group (n=1443) Dual group (n=1656) Inverse-Probability-of-Treatment-Weighted (IPTW) for the Entire cohort Propensity score matching (965 pairs) Dual antiplatelet group (n=965) Triple antiplatelet group (n=965) Clinical follow-up at 12 months (Death, MI, or stent thrombosis)

  3. 12-month clinical outcomes Study endpoint Primary endpoint Death Myocardial infarction Stent thrombosis (definite and probable by ARC) Secondary endpoint • Death or Myocardial infarction • TIMI Major bleeding • TIMI minor bleeding

  4. Twelve-month risk of Events after DES Implantation of Triple versus Dual antiplatelet therapy according to analytic methods Variables Crude Inverse-probability-of-treatment weighted Propensity-matched (965 pairs) Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value Cardiac events Death 0.925 (0.521 -1.644) 0.7907 0.762 (0.401-1.448) 0.4062 0.644(0.300-1.381) 0.2584 MI 0.381 (0.138-1.048) 0.0617 0.233 (0.077-0.703) 0.0097 0.298 (0.082-1.086) 0.0665 Stent thrombosis 0.286 (0.081-1.013) 0.0524 0.136 (0.035-0.521) 0.0036 0.124 (0.016-0.996) 0.0496 Death/MI 0.761 (0.464-1.251) 0.2817 0.591 (0.3364-1.037) 0.0665 0.556 (0.287-1.075) 0.0811 Bleeding Major bleeding 0.850 (0.477-1.516) 0.5830 0.969 (0.443-2.119) 0.9372 0.683 (0.343-1.360) 0.2781 Minor bleeding 1.039 (0.757-1.426) 0.8125 1.062 (0.734-1.537) 0.7504 1.045 (0.703-1.555) 0.8267 Hazard ratios are for the triple group, as compared with the dual group.

  5. Adjusted Landmark Analysis using IPTW in patients without events at landmark months Triple therapy beyond 1 month, Triple therapy (n=974) vs. Dual therapy (n=1646) Outcome HR 95%CI p-value Death 1.192 0.591 2.403 0.6238 Myocardial infarction 0.346 0.088 1.365 0.1295 Stent thrombosis 0.108 0.013 0.918 0.0415 Death/ Myocardial infarction 0.931 0.493 1.758 0.8262 Triple therapy beyond 3 month, Triple therapy (n=394) vs. Dual therapy (n=1638) Outcome HR 95%CI p-value Death 0.832 0.183 3.776 0.8116 MI 0.553 0.066 4.615 0.5841 Stent thrombosis NA NA NA NA Death/ Myocardial infarction 0.754 0.210 2.704 0.6645 Triple therapy beyond 6 month, Triple therapy (n=253) vs. Dual therapy (n=1631) Outcome HR 95%CI p-value Death 0.709 0.090 5.570 0.7441 MI NA Stent thrombosis NA Death/ Myocardial infarction 0.474 0.062 3.611 0.4711

More Related